



# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead program, CTX001, aims to treat Sickle cell disease and  $\beta$ -thalassemia using an ex vivo approach. We are also pursuing oncology indications with our allogeneic CAR-T platform and liver, lung, and neuromuscular indications using in vivo approaches. In addition, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and select business operations in London, United Kingdom.

## PRIMARY IR CONTACT


Chris Brinzey  
Westwicke Partners  
**Phone:** 339-970-2843  
**E-mail:**  
chris.brinzey@westwicke.com

## STOCK PERFORMANCE

### CRSP (Common Stock)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	<b>\$29.73</b>
<b>Change (%)</b>	▼ 0.35 (1.16%)
<b>Volume</b>	386,254
<b>52 Week Low</b>	\$11.63
<b>Market Cap</b>	\$1,364,338,062
<b>Rolling EPS</b>	-0.32
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	45,890,954

Data as of 01/19/18 4:00 p.m. ET



## RECENT HEADLINES & EVENTS

Jan-04-2018 - 7:03 p.m.  
CRISPR Therapeutics Announces Pricing of  
Public Offering of Common Shares

There are currently no events scheduled.

Jan-03-2018 - 6:15 a.m.  
CRISPR Therapeutics Announces Proposed  
Public Offering of Common Shares

Dec-21-2017 - 8:00 a.m.  
CRISPR Therapeutics Announces Appointment of  
Dr. Rodger Novak as Chairman of the Board

## SEC FILINGS

<b>Filing Date</b>	<b>Form</b>
01/18/18	4
01/16/18	SC 13D/A
01/11/18	4
01/09/18	4

*Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources*